SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products. The Company’s key Radiopharmaceutical Oncology product is Pylarify, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Lantheus Holdings, Inc. (LNTH) Misled Investors About Pylarify's Competitive Position

According to the complaint, during the class period, defendants disseminated materially false and misleading statements concerning the true state of Pylarify’s competitive position. Specifically, that Lantheus was not equipped to properly assess the pricing and competitive dynamics for Pylarify; the Company failed to properly disclose that its early 2025 price increase, issued despite price erosion the year prior, created an opportunity for competitive pricing to flourish, risking Pylarify’s price point, revenue, and overall growth potential.

Plaintiff alleges that in truth, Lantheus’ optimistic reports of Pylarify’s sales growth potential and pricing normalization fell short of reality. Lantheus, despite defendants' claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify’s market.

On August 6, 2025, Lantheus announced disappointing results and significantly reduced growth expectations for Pylarify, which had fallen 8.3% year-over-year, and slashed fiscal year 2025 growth projections further. Defendants again attributed the losses to the ongoing competition, impacting Pylarify’s pricing dynamics. On this news, the price of Lantheus’ common stock plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, a decline of about 28.8% in the span of one day.

What Now: You may be eligible to participate in the class action against Lantheus Holdings, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP by the November 10, 2025 lead plaintiff deadline. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Lantheus Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.